Cardiac Science Provides Update On Artema Acquisition; Acceptance Period is Extended.

Business Editors & Health/Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--May 31, 2001

Cardiac Science Inc. (Nasdaq:DFIB) today announced that it has extended the acceptance period relating to its offer to acquire all of the issued and outstanding shares of Artema Medical AB, a Swedish developer and manufacturer of patient monitors and external defibrillator devices, from June 4, 2001, to June 18, 2001.

The extension is the result of the routine review process associated with Cardiac Science's filings with the U.S. Securities and Exchange Commission relating to the planned acquisitions of both Artema and Survivalink Corp. Although Cardiac Science anticipates closing the Artema transaction in June, it is possible that an additional extension to the acceptance period may be required.

Cardiac Science announced on Jan. 10, 2001, that it had tendered an offer to acquire all of the issued and outstanding shares of Artema. As consideration, Cardiac Science will issue approximately 4,444,444 shares of its common stock. Cardiac's offer is conditional upon, among other things, the tender of at least 90% of the issued and outstanding shares of Artema.

About Artema Medical

Artema develops, manufactures and markets bedside and portable multi-parameter patient monitors and defibrillator devices used in cardiac and emergency care applications inside and outside of hospitals. Artema's products are exported to more than 80 countries via independent distributors encompassing Europe, Asia and the Middle East.

About Cardiac Science

Cardiac Science develops, manufactures and markets life-saving external cardiac defibrillator devices that monitor and automatically treat patients who suffer life-threatening heart rhythms. The company's core proprietary tachyarrhythmia detection, defibrillation and electrode technology platform has multiple applications, including use in external and wearable defibrillators and with standard patient monitors widely used in hospitals throughout the world.

The growth of the company's installed base provides a potential recurring revenue stream from the sale of the company's proprietary disposable defibrillator electrodes. For more information on Cardiac Science, visit its Internet site at www.cardiacscience.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward-looking statements include, but are not limited to, the closing of the transaction between Cardiac Science Inc. and the shareholders of Artema Medical AB, the life-saving potential of Cardiac Science's technology and the applications of the company's technology. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the company's Form 10-K for the year ending Dec. 31, 2000, and other documents filed by the company with the SEC.

The company has filed a registration statement on Form S-4 with the SEC in connection with the offer. The company urges you to read the registration statement and any other relevant documents filed or to be filed with the SEC because they contain important information. Investors and stockholders are able to obtain free copies of these documents at the commission's Web site at www.sec.gov and upon oral or written request to Cardiac Science Inc., 16931 Millikan Ave., Irvine, Calif. 92606, Attention: Roderick de Greef, Chief Financial Officer (telephone number: 949/587-0357). You should read the registration statement carefully before making a decision concerning the transaction.